Search | Clinical Trials Finder

Conditions: Kartagener Syndrome
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: Not listed
Enrollment: 1,800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Lung Diseases, Pulmonary Embolism
Interventions: Magnetic Resonance Angiography, Magnetic Resonance Venography; Procedure
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older
Enrollment: 1,256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 8
States / cities: Atlanta, Georgia • Bethesda, Maryland • Rockville, Maryland + 5 more

Conditions: Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Lumbar Puncture, Magnetic Resonance Imaging; Procedure · Device
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Asthma (Diagnosis)
Interventions: WIN378, Placebo; Drug
Lead sponsor: Windward Bio; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 21
States / cities: Los Angeles, California • San Jose, California • Melbourne, Florida + 18 more

Conditions: Lung Transplantation
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Los Angeles, California • St Louis, Missouri

Conditions: HIV-1-infection, HIV Disease Progression, Inflammation, HIV
Interventions: Venipuncture, Targeted physical medical exam, Urine pregnancy test, Anoscopy, Esophagogastroduodenoscopy (EGD); Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
Interventions: ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Trastuzumab emtansine; Drug
Lead sponsor: Enliven Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 5
States / cities: Aurora, Colorado • Orlando, Florida • Plantation, Florida + 2 more

Conditions: Lung Cancer
Interventions: docetaxel; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Brain Metastases, Lung Cancer, Breast Cancer, Melanoma, Malignant Glioma
Interventions: 2B3-101, Trastuzumab, 2B3-101 60 mg/m2 every 4 weeks, 2B3-101 50 mg/m2 every 3 weeks; Drug
Lead sponsor: BBB-Therapeutics B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Interstitial Lung Disease
Interventions: Transbronchial biopsy, Cryoprobe biopsy, VATS biopsy; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: indacaterol/glycopyrrolate, indacaterol, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: St Louis, Missouri • Charlotte, North Carolina • Raleigh, North Carolina

Conditions: Electronic Cigarette Related Lung Damage
Interventions: Hyperpolarized xenon 129, Cardiopulmonary Stress Test, Pulmonary Function Test, Chest CT; Drug · Diagnostic Test
Lead sponsor: Y. Michael Shim, MD; Other
Eligibility: 18 Years to 35 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2032
U.S. locations: 2
States / cities: Durham, North Carolina • Charlottesville, Virginia

Conditions: Non-Small Cell Lung Cancer
Interventions: Durvalumab, Danvatirsen, Ceralasertib, Vistusertib, Olaparib, Oleclumab, Trastuzumab deruxtecan, Cediranib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 528 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 17
States / cities: Duarte, California • Fullerton, California • La Jolla, California + 12 more

Conditions: COPD, Healthy, Constrictive Bronchitis
Interventions: hyperpolarized helium-3 gas with MRI of the chest; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2026
U.S. locations: 2
States / cities: Charlottesville, Virginia

Conditions: Pulmonary Hypertension, Interstitial Lung Disease
Interventions: Treprostinil Palmitil Inhalation Powder, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 11
States / cities: Los Angeles, California • Santa Barbara, California • Gainesville, Florida + 8 more

Conditions: Healthy Participants
Interventions: AZD8965, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 147 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Glendale, California

Conditions: Lung Transplantation
Interventions: OCS Lung System; Device
Lead sponsor: TransMedics; Industry
Eligibility: 18 Years and older
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 18
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 14 more

Conditions: COPD, COPD Exacerbation
Interventions: Sylvee; Device
Lead sponsor: Respira Labs, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Mountain View, California

Conditions: COVID-19, Pneumonia
Interventions: LY3127804, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 13
States / cities: Phoenix, Arizona • Tucson, Arizona • Denver, Colorado + 10 more

Conditions: Non-Small-Cell Lung Adenocarcinoma, Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Metastatic
Interventions: Docetaxel, Ganetespib; Drug
Lead sponsor: Synta Pharmaceuticals Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 696 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 78
States / cities: Flagstaff, Arizona • Prescott Valley, Arizona • Sedona, Arizona + 66 more

Conditions: Systemic Sclerosis
Interventions: Nemolizumab, Placebo; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Arlington, Texas

Conditions: Lung Cancer, Squamous Cell Carcinoma, Head and Neck Cancer, Hepatic Carcinoma, Renal Cell Carcinoma
Interventions: [F-18] VM4-037; Drug
Lead sponsor: Siemens Molecular Imaging; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cystic Fibrosis (CF), Chronic Kidney Disease(CKD), Acute Kidney Injury
Interventions: Not listed
Lead sponsor: University of Virginia; Other
Eligibility: 7 Years and older
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Birmingham, Alabama • Lebanon, New Hampshire • Charlottesville, Virginia

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 10
States / cities: Birmingham, Alabama • Miami, Florida • Cordele, Georgia + 7 more

Search by objective public record fields.

Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease

Prospective Investigation of Pulmonary Embolism Diagnosis III

Lumbar Punctures for the Detection of ctDNA in the Cerebrospinal Fluid of Patients With Stage III and IV Non-Small Cell Lung Cancer

Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma

Live Lung Donor Retrospective Study

Comparing Immune Activation and Latent HIV Reservoir Size Between People Living With HIV on Tenofovir-containing Versus NRTI-free ART

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

Two Regimens of Docetaxel in Treating Patients Who Have Not Received Chemotherapy For Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Comparison of Transbronchial, Cryoprobe, and VATS Biopsy for the Diagnosis of Interstitial Lung Disease

Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Dissolved Phase HXe-129 MRI: A Novel Biomarker to Quantify Pulmonary Pathology

Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

Study of Airflow in the Lungs Using Helium MRI

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants

OCS™ Lung TOP Registry For Donor Lungs for Transplantation

Clinical Feasibility of a Non-invasive Wearable Acoustic Device for Measuring Air Trapping in COPD

A Study of LY3127804 in Participants With COVID-19

A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC

A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis

An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037

Kidney Function in People With Cystic Fibrosis in the Era of HEMT

A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.